NDA 022278 · Dorc
Membraneblue
Trypan Blue · Ophthalmic
Priority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Feb 20, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 1 recruiting
FAERS reports
34
32 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 24, 2025.
MembraneBlue 0.15% - Indications & Usage Section MembraneBlue™ 0.15% is indicated for use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue in adults and pediatric patients. These highlights do not include all the information needed to use MEMBRANEBLUE™ safely and effectively. See full prescribing information for MEMBRANEBLUE. MEMBRANEBLUE (trypan blue ophthalmic solution) 0.15%, for intraocular ophthalmic use Initial U.S. Approval: 2004 MembraneBlue is a diagnostic dye indicated for use as an aid in ophthalmic posterior surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of epiretinal tissue in adults and pediatric patients
Mechanism: MembraneBlue 0.15% - Mechanism of action section. MembraneBlue 0.15% selectively stains membranes in the human eye during posterior surgery, such as epiretinal membranes (ERM) and Internal Limiting Membranes (ILM).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 20, 2009 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
1 products under this application
- MEMBRANEBLUE · TRYPAN BLUE 0.15% · SOLUTION, OPHTHALMIC · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Trypan Blue" as an intervention, any sponsor and status, largest first.
Hayat Abad Medical Complex, PeshawarGovernment (non-federal)
NCT07735000 · 60 participants · Start Mar 22, 2024 · Primary completion Sep 22, 2024
Drug: Trypan Blue · For: Age Related Cataract; Cataract
Sites: Peshawar, Pakistan
- Descemet Endothelial Thickness Comparison TrialStatus unknown
Oregon Health and Science UniversityAcademic, hospital or other
NCT02373137 · 38 participants · Start Jan 22, 2015 · Primary completion Apr 4, 2018
Drug: Prednisolone; Ofloxacin and 2 more · For: Keratoplasty; Grafting, Corneal; Transplantation, Corneal and 2 more
Sites: Palo Alto, California; San Francisco, California; Portland, Oregon
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
NCT07813884 · 15 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 1, 2027
Drug: BPR001-615 · For: Colorectal Adenocarcinoma
Sites: Nice, France
Makerere UniversityAcademic, hospital or other
NCT04553159 · 8 participants · Start Mar 1, 2021 · Primary completion Jun 16, 2021
Drug: Autologous adipose derived stem cells · For: Keloid; Autologus Adipose Derived Stem Cells; Feasibility and 1 more
Sites: Kampala, Uganda
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blindness22
- toxic anterior segment syndrome21
- corneal oedema6
- product quality issue6
- cerebral infarction3
- pigmentation disorder3
- thyroid disorder3
- condition aggravated2
- off label use2
- vision blurred2
- corneal degeneration1
- drug interaction1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 21 |
| 2016 | 6 |
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Analysis of success rate of organoid construction of nasopharyngeal carcinoma by first-day suspension method].
Huo HM, Yao X, Lai YJ, et al. · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2023 · Randomized Controlled Trial, English Abstract
- The role of novel DMEK graft shapes in facilitating intraoperative unscrolling.
Modabber M, Talajic JC, Mabon M, et al. · Graefes Arch Clin Exp Ophthalmol 2018 · Randomized Controlled Trial
- Use of Brilliant Blue G in Descemet's Membrane Endothelial Keratoplasty.
Hayashi T, Yuda K, Oyakawa I, et al. · Biomed Res Int 2017 · Clinical Trial, Comparative Study
- Impact of β-glucan on the Fecal Water Genotoxicity of Polypectomized Patients.
Turunen KT, Pletsa V, Georgiadis P, et al. · Nutr Cancer 2016 · Randomized Controlled Trial
- Effect of levobupivacaine on articular chondrocytes: an in-vitro investigation.
Cobo-Molinos J, Poncela-Garcia M, Marchal-Corrales JA, et al. · Eur J Anaesthesiol 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Endothelial cell integrity after phacoemulsification with 2 different handpieces.
Vargas LG, Holzer MP, Solomon KD, et al. · J Cataract Refract Surg 2004 · Clinical Trial, Randomized Controlled Trial
Sponsor: Dorc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.